Market News

Galapagos NV (GLPG) EPS Estimated At $-0.70; South Street Advisors Has Increased Flextronics Int’l (FLEX) Position

Analysts expect Galapagos NV (NASDAQ:GLPG) to report $-0.70 EPS on February, 23.They anticipate $1.75 EPS change or 166.67% from last quarter’s $1.05 EPS. After having $-0.85 EPS previously, Galapagos NV’s analysts see -17.65% EPS growth. The stock decreased 1.20% or $1.4 during the last trading session, reaching $115.33. About 68,142 shares traded. Galapagos NV (NASDAQ:GLPG) has risen 65.27% since February 17, 2017 and is uptrending. It has outperformed by 48.57% the S&P500.

South Street Advisors Llc increased Flextronics Int’l (FLEX) stake by 13.39% reported in 2017Q3 SEC filing. South Street Advisors Llc acquired 26,900 shares as Flextronics Int’l (FLEX)’s stock rose 0.43%. The South Street Advisors Llc holds 227,840 shares with $3.78M value, up from 200,940 last quarter. Flextronics Int’l now has $9.41 billion valuation. The stock increased 0.11% or $0.02 during the last trading session, reaching $17.84. About 4.04M shares traded or 13.14% up from the average. Flex Ltd. (NASDAQ:FLEX) has risen 35.11% since February 17, 2017 and is uptrending. It has outperformed by 18.41% the S&P500.

Galapagos NV, a clinical-stage biotechnology company, develops and commercializes novel medicines in Belgium, Croatia, France, and the Netherlands. The company has market cap of $5.54 billion. The Company’s clinical stage programs include filgotinib, which is in Phase III clinical trial for the treatment of rheumatoid arthritis, Crohn's disease, and ulcerative colitis; GLPG1690, which is in Phase IIa clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972, which is in Phase 1 clinical trial for the treatment of osteoarthritis; and MOR106 that is in atopic dermatitis patients in Phase Ib trial. It currently has negative earnings. The firm has collaboration agreement with Gilead Sciences, Inc. for the development of filgotinib for inflammatory indications; Servier to develop GLPG1972; and AbbVie for discovery, development, and commercialization of potentiator and corrector molecules for the treatment of cystic fibrosis, as well as with MorphoSys for MOR106.

Among 9 analysts covering Galapagos NV (NASDAQ:GLPG), 6 have Buy rating, 0 Sell and 3 Hold. Therefore 67% are positive. Galapagos NV had 28 analyst reports since August 11, 2015 according to SRatingsIntel. The stock has “Hold” rating by Stifel Nicolaus on Friday, July 28. Morgan Stanley maintained Galapagos NV (NASDAQ:GLPG) rating on Monday, May 2. Morgan Stanley has “Overweight” rating and $89 target. The firm earned “Hold” rating on Friday, October 27 by RBC Capital Markets. The company was upgraded on Friday, August 11 by Stifel Nicolaus. The firm has “Buy” rating given on Tuesday, August 30 by Janney Capital. BTIG Research maintained the stock with “Buy” rating in Wednesday, February 7 report. The firm earned “Buy” rating on Friday, August 11 by Nomura. BTIG Research maintained Galapagos NV (NASDAQ:GLPG) on Monday, January 8 with “Buy” rating. The stock of Galapagos NV (NASDAQ:GLPG) earned “Buy” rating by Cowen & Co on Tuesday, June 20. As per Thursday, September 14, the company rating was maintained by Stifel Nicolaus.

Among 15 analysts covering Flextronics International Ltd. (NASDAQ:FLEX), 11 have Buy rating, 1 Sell and 3 Hold. Therefore 73% are positive. Flextronics International Ltd. had 48 analyst reports since July 28, 2015 according to SRatingsIntel. The company was maintained on Tuesday, February 21 by RBC Capital Markets. The rating was maintained by Needham on Wednesday, August 30 with “Buy”. RBC Capital Markets maintained the shares of FLEX in report on Thursday, January 25 with “Buy” rating. Goldman Sachs upgraded the stock to “Buy” rating in Tuesday, September 20 report. The stock of Flex Ltd. (NASDAQ:FLEX) earned “Neutral” rating by Citigroup on Wednesday, October 21. Argus Research upgraded it to “Buy” rating and $13 target in Friday, January 29 report. The rating was maintained by RBC Capital Markets on Monday, January 18 with “Outperform”. The rating was maintained by Needham on Friday, January 27 with “Buy”. JP Morgan initiated it with “Overweight” rating and $15 target in Tuesday, April 26 report. As per Monday, July 24, the company rating was maintained by RBC Capital Markets.

Leave a Reply

Your email address will not be published. Required fields are marked *